Melissa Andel, M.P.P., of CommonHealth Solutions LLC, says there has been some retreat from earlier proposals for severe regulation to an emphasis on disclosure and transparency.
All legislative and political jockeying around tightening regulation of pharmacy benefit managers (PBMs) has reified into four bills, one in the House and three in the Senate that have emerged from three different committees. Today at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 meeting in Orlando, Melissa Andel, M.P.P., outlined the PBM legislation and shared insights into which provisions stand the best chance of surviving and becoming law.
In a Zoom interview with Managed Healthcare Executive prior to the meeting, Andel described some of the themes of the legislation.
The Senate bills differ, partly because the three committees that have considered PBM legislation have different jurisdictions. Andel said some of the common threads running through the legislation that Congress has debated include rebate pass throughs (to the health plan, not to individual patients), a variety of new transparency and disclosure requirements and, in some bills, a ban on spread pricing.
Delinking PBM administrative fees from the price of drugs has a lot of support, Andel noted: “Congress is really trying to move away from incentives that encourage manufacturers to continue to increase list prices so they can increase rebates.”
Andel observed that the provisions of the current crop of bills would, if they become law, mean milder change for the PBM industry than some earlier versions. The emphasis has shifted, she said, to disclosure and transparency about rebates, acquisition costs and other details rather than outright bans on some of the PBM business practices that have been criticized by some lawmakers and industry critics,
“What we have seen overall is a roll back in some of the more severe or harsh PBM regulation,” Andel said.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
October 22nd 2024There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More